Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 10.08%47.78B | 4.61%182.26B | 2.23%137.67B | 1.77%86.29B | -2.68%43.41B | 8.94%174.22B | 12.70%134.66B | 18.04%84.79B | 30.97%44.6B | 83.70%159.93B |
| Operating income | 10.08%47.78B | 4.61%182.26B | 2.23%137.67B | 1.77%86.29B | -2.68%43.41B | 8.94%174.22B | 12.70%134.66B | 18.04%84.79B | 30.97%44.6B | 83.70%159.93B |
| Cost of sales | ---- | -0.49%-83.45B | ---- | 1.47%-40.66B | ---- | -8.13%-83.05B | ---- | -20.01%-41.27B | ---- | -49.88%-76.8B |
| Operating expenses | -7.27%-42.61B | -0.49%-83.45B | -0.68%-121.56B | 1.47%-40.66B | 0.00%-39.73B | -8.13%-83.05B | -13.52%-120.74B | -20.01%-41.27B | -19.32%-39.73B | -49.88%-76.8B |
| Gross profit | 40.41%5.17B | 8.36%98.8B | 15.66%16.1B | 4.85%45.63B | -24.49%3.68B | 9.68%91.18B | 6.00%13.92B | 16.23%43.52B | 540.74%4.88B | 132.09%83.13B |
| Selling expenses | -15.57%-2.08B | -4.73%-7.15B | -7.00%-5.54B | -5.60%-3.36B | -11.12%-1.8B | -7.59%-6.83B | -7.97%-5.17B | -10.69%-3.18B | -21.75%-1.62B | -45.79%-6.35B |
| Administrative expenses | -0.28%-1.08B | -3.16%-4.58B | -4.11%-3.14B | -2.96%-2.13B | -7.69%-1.08B | -6.87%-4.44B | -9.99%-3.02B | -7.39%-2.06B | -14.79%-1B | -18.20%-4.15B |
| Research and development expenses | 1.88%-157M | ---- | -4.47%-397M | ---- | -19.40%-160M | ---- | -0.80%-380M | ---- | -17.54%-134M | ---- |
| Profit from asset sales | -7.14%13M | ---- | -80.42%65M | ---- | -82.28%14M | ---- | 33.33%332M | ---- | -50.63%79M | ---- |
| Depreciation and amortization | ---- | -10.12%-31.21B | ---- | -7.16%-14.93B | ---- | -4.33%-28.34B | ---- | -7.22%-13.94B | ---- | -11.95%-27.17B |
| Revaluation surplus | -0.97%408M | ---- | 89.55%381M | ---- | 464.38%412M | ---- | -64.98%201M | ---- | 247.62%73M | ---- |
| -Changes in the fair value of other assets | -0.97%408M | ---- | 89.55%381M | ---- | 464.38%412M | ---- | -64.98%201M | ---- | 247.62%73M | ---- |
| Impairment and provision | ---- | -100.99%-3M | 50.00%3M | ---- | ---- | 145.53%302M | 128.57%2M | --304M | ---- | 127.39%123M |
| -Impairment of property, machinery and equipment | ---- | -100.99%-3M | ---- | ---- | ---- | --302M | ---- | --304M | ---- | ---- |
| -Other impairment is provision | ---- | ---- | 50.00%3M | ---- | ---- | ---- | 128.57%2M | ---- | ---- | 127.39%123M |
| Special items of operating profit | 284.83%1.24B | -6.28%-46.28B | 58.41%2.51B | -8.70%-21.89B | -64.62%323M | -8.78%-43.55B | -51.78%1.59B | -10.54%-20.14B | 5.43%913M | -55.29%-40.03B |
| Adjustment items of operating profit | ---- | ---- | -50.00%-6M | ---- | ---- | ---- | ---4M | ---- | ---- | ---- |
| Operating profit | 168.23%3.37B | 15.08%9.58B | 36.24%9.56B | -26.27%3.32B | -58.93%1.26B | 49.85%8.33B | -21.66%7.02B | 214.52%4.51B | 570.46%3.06B | 124.65%5.56B |
| Financing income | -3.70%104M | 57.21%338M | 66.45%258M | 45.26%138M | 74.19%108M | -40.44%215M | -51.41%155M | -56.62%95M | -48.76%62M | -21.01%361M |
| Financing cost | -5.47%-1.39B | 3.56%-5.55B | 9.66%-3.92B | 4.05%-2.79B | 11.01%-1.32B | 2.87%-5.76B | 1.36%-4.34B | 2.02%-2.91B | 0.13%-1.48B | 1.30%-5.93B |
| Share of profits of associates | ---- | 39.39%-754M | ---- | 35.30%-854M | ---- | 44.56%-1.24B | ---- | -7,433.33%-1.32B | ---- | -17,161.54%-2.24B |
| Share of profit from joint venture company | ---- | 30.10%817M | ---- | 84.04%519M | ---- | 15.02%628M | ---- | 1.08%282M | ---- | 79.61%546M |
| Special items of earning before tax | 60.78%164M | 152.58%377M | -73.74%584M | 187.54%260M | 59.38%102M | -483.42%-717M | 590.68%2.22B | 60.03%-297M | 0.00%64M | 104.99%187M |
| Earning before tax | 8,003.03%2.67B | 231.36%4.81B | 22.97%6.09B | 66.39%594M | -97.92%33M | 195.40%1.45B | 24.94%4.96B | 120.24%357M | 212.83%1.58B | 95.18%-1.52B |
| Tax | ---- | -49.02%-2.13B | ---- | -86.54%-1.43B | ---- | 0.70%-1.43B | ---- | -6.69%-765M | ---- | 33.70%-1.44B |
| After-tax profit from continuing operations | 682.93%2.15B | 10,632.00%2.68B | 8.44%4B | -104.17%-833M | -129.38%-369M | 100.85%25M | 33.03%3.69B | 83.56%-408M | 172.85%1.26B | 91.23%-2.96B |
| Earning after tax | 682.93%2.15B | 10,632.00%2.68B | 8.44%4B | -104.17%-833M | -129.38%-369M | 100.85%25M | 33.03%3.69B | 83.56%-408M | 172.85%1.26B | 91.23%-2.96B |
| Minority profit | 77.25%670M | 1.90%1.83B | -1.80%1.69B | 8.51%701M | -24.40%378M | 51.65%1.79B | 18.62%1.72B | 63.13%646M | 187.36%500M | 216.32%1.18B |
| Profit attributable to shareholders | 298.26%1.48B | 148.33%855M | 17.40%2.31B | -45.54%-1.53B | -198.81%-747M | 57.27%-1.77B | 48.86%1.97B | 63.36%-1.05B | 139.83%756M | 87.34%-4.14B |
| Basic earnings per share | 300.00%0.08 | 150.00%0.05 | 18.18%0.13 | -33.33%-0.08 | -200.00%-0.04 | 56.52%-0.1 | 57.14%0.11 | 62.50%-0.06 | 140.00%0.04 | 87.89%-0.23 |
| Diluted earnings per share | 240.00%0.07 | 150.00%0.05 | 9.09%0.12 | -33.33%-0.08 | -225.00%-0.05 | 56.52%-0.1 | 120.00%0.11 | 62.50%-0.06 | 140.00%0.04 | 87.89%-0.23 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | ShinWing Certified Public Accountants (Hong Kong) Limited, ShinWing Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership), KPMG Accounting Firm | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership), KPMG Accounting Firm |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.